Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through …

MDS-UPDRS motor scores demonstrated stability to baseline recorded at study entry with no disease progression among the 12 ...
Yahoo Finance

Annovis Bio Announces New Data from Phase III Parkinson’s Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition after ...

Changes in MDS-UPDRS after treatment with 10mg or 20mg buntanetap in patients with a PD diagnosis over 3 years compared to baseline and placebo MALVERN, Pa., July 02, 2024 (GLOBE NEWSWIRE) -- via IBN ...
The American Journal of Managed Care

Daily Niacin Enhancement Linked With Improved QOL, Slower Parkinson Disease Progression

Low-dose niacin uptake over 12 months was associated with improvements in the UPDRS III motor score, as well as fatigue and mood in people with Parkinson disease. Niacin enhancement may lead to ...
Financial Times

Annovis Bio Announces New Data from Phase III Parkinson’s Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition after ...

Buntanetap showed dose-dependent and statistically significant improvements in cognition in the overall enrolled PD population. Parkinson’s patients with substantial cognitive decline exhibited a very ...